Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)
Status:
Active, not recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
Forty-five subjects receiving no dietary therapy with a proven G1D diagnosis will be
enrolled. To evaluate the effect of C7 supplementation of a regular diet on a EEG activity in
addition to IQ, language, working memory, processing speed, emotional and behavioral
functioning, ataxia, and other neuropsychological and neurological performance indices in
children and adults genetically diagnosed with G1D receiving a regular diet at enrollment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)